Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07400575 | Anlotinib in Cross-line Treatment of NSCLC and SCLC(NSCLC SCLC) | not yet recruiting | — | 350 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 10, 2026 | clinicaltrials |
| NCT07395375 | Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection(NIVA-TSLR) | not yet recruiting | N/A | 1,600 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER |
| 1 |
| Feb 9, 2026 |
| clinicaltrials |
| NCT07398027 | Post-Market Study of Transbronchial Cryo-assisted RFA During Robotic Bronchoscopy With Subsequent Surgical Resection(CRONOS-CH) | not yet recruiting | N/A | 20 | Carolin SteinackOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07392073 | Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC | not yet recruiting | — | 80 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07393555 | Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) | not yet recruiting | Phase 2 | 117 | SWOG Cancer Research NetworkNETWORK | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07229339 | Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 16 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07388875 | Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC(SKB264-ANLO) | not yet recruiting | Phase 2 | 30 | China Medical University, ChinaOTHER | 0 | Feb 5, 2026 | clinicaltrials |
| NCT07381543 | Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone | not yet recruiting | Phase 2 | 76 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07383116 | Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 500 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07383454 | Lung Cancer Screening in Population Who Had Never Smoked | not yet recruiting | N/A | 2,500 | Chung Shan Medical UniversityOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT06348030 | Totally Robotic Versus Surgeon-Assisted Robotic Lung Resection For Early-Stage NSCLC | not yet recruiting | N/A | 120 | St. Joseph's Healthcare HamiltonOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06638125 | 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial | not yet recruiting | Phase 1 / Phase 2 | 89 | St. Joseph's Healthcare HamiltonOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07377916 | Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC(NSCLC) | not yet recruiting | N/A | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jan 30, 2026 | clinicaltrials |
| NCT07375979 | A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study | not yet recruiting | — | 14,300 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376499 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 2 | 31 | China Medical University, ChinaOTHER | 0 | Jan 29, 2026 | clinicaltrials |
| NCT07376512 | Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis(EVpredict) | not yet recruiting | — | 378 | Centre Georges Francois LeclercOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07372378 | Association of Different Tidal Volumes and Postoperative Pulmonary Complications | not yet recruiting | — | 650 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07373171 | Evaluation of Different Sizes of Left-Sided Double-Lumen Tubes for Thoracic Surgery in a Tertiary Level Teaching Hospital | not yet recruiting | N/A | 60 | Tribhuvan University, NepalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07370805 | 18F-FAPI PET in Lung Cancer | not yet recruiting | — | 120 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07365410 | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study | not yet recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07357532 | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD | not yet recruiting | Phase 2 | 44 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358884 | First in Human Study of QLS5316 in Solid Tumors | not yet recruiting | Phase 1 | 300 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jan 22, 2026 | clinicaltrials |
| NCT07298148 | Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg | not yet recruiting | Phase 2 | 28 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 21, 2026 | clinicaltrials |
| NCT07351565 | Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer(CPPGPTCLC) | not yet recruiting | Phase 1 | 22 | Chang ChenOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07352176 | Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions | not yet recruiting | N/A | 40 | Guangzhou Medical UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07353476 | Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC | not yet recruiting | Phase 2 | 38 | Shanghai Zhongshan HospitalOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07347977 | Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk(LidCRM) | not yet recruiting | N/A | 1,400 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07343479 | Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases | not yet recruiting | Phase 2 | 45 | Zhejiang Cancer HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07289646 | Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy(Pegasus 2) | not yet recruiting | Phase 3 | 418 | University Hospital, BrestOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07339839 | Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 42 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT07331701 | Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study | not yet recruiting | — | 60 | Seoul National University HospitalOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06822348 | Short-term Effects of Osteopathic Manipulations on Heart Rate Variability in Lung Cancer Patients - A Randomized Pilot Study | not yet recruiting | N/A | 80 | Centre Hospitalier Henri Duffaut - AvignonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07318636 | NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC | not yet recruiting | Phase 1 | 10 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07308379 | Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer | not yet recruiting | — | 1,200 | Fudan UniversityOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07303881 | Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer(JACKPOT22) | not yet recruiting | Phase 2 | 16 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07294261 | Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC | not yet recruiting | Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07287904 | Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data | not yet recruiting | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07289048 | A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT07285148 | A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 253 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07286539 | Precision Physical Exercise for Personalized Onco-Hematology.(PEPOH) | not yet recruiting | N/A | 150 | University of SalamancaOTHER | 0 | Dec 16, 2025 | clinicaltrials |
| NCT07286942 | Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial | not yet recruiting | Phase 2 | 24 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07281209 | A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 40 | Shanghai Chest HospitalOTHER | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07283198 | A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 160 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07280559 | Evaluation of AI-assisted LDCT Screening in Lung Cancer | not yet recruiting | N/A | 1,120 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Dec 12, 2025 | clinicaltrials |
| NCT07277088 | The Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy | not yet recruiting | N/A | 158 | Jiayuan SunOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07274384 | Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial(HYPERBOLIC) | not yet recruiting | Phase 2 | 74 | Università Vita-Salute San RaffaeleOTHER | 0 | Dec 10, 2025 | clinicaltrials |
| NCT07271602 | A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. | not yet recruiting | Phase 2 | 104 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07272057 | SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes | not yet recruiting | N/A | 200 | Shanghai Chest HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07273279 | ADH1B and ALDH Gene Variants and Lung Cancer Risk(ALDH) | not yet recruiting | — | 100,000 | Kaohsiung Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT06882174 | This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer(TIME-NSCLC) | not yet recruiting | Phase 2 | 58 | AHS Cancer Control AlbertaOTHER | 0 | Dec 8, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 10, 2026source: clinicaltrials